| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 06/23/2009 | US7550426 Acetylated therapeutic procytotoxins |
| 06/23/2009 | US7550425 Diuretic peptide conjugates |
| 06/23/2009 | US7550423 Modulate hormone release; controlling neurotransmitter release |
| 06/23/2009 | US7550282 Biological glue based on thrombin-conjugated nanoparticles |
| 06/23/2009 | US7550263 Fetoproteins; pharmacokinetics; biocompatability; rheumatoid arthritis; multiple sclerosis; cancer |
| 06/23/2009 | US7550159 For treatment of cancer and autoimmune diseases; kits |
| 06/23/2009 | US7550157 Method for the preparation of polymeric micelle via phase separation of block copolymer |
| 06/23/2009 | US7550146 Mucin motif found on epithelial tumor cell surfaces; antibody induction; cancer treatment |
| 06/23/2009 | US7550145 Adjuvant compositions |
| 06/23/2009 | US7550144 Antibody capable of reacting with cellular prion protein (PrP) ; for prevention of prion replication; for treatment or prevention of neuropathology such as Creutzfeldt-Jacob Disease |
| 06/23/2009 | US7550143 Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses |
| 06/23/2009 | US7550142 Anti-integrin antibodies, compositions, methods and uses |
| 06/23/2009 | US7550140 Stimulation of human T-cells and used to enhance antigen-specific immune responses; immunotherapy |
| 06/23/2009 | CA2521509C Fast dissolving orally consumable films containing pharmaceutically active agents |
| 06/23/2009 | CA2389219C Dry powder compositions having improved dispersivity |
| 06/23/2009 | CA2373466C Application of aprataxin gene to diagnosis and treatment for early-onset spinocerebellar ataxia (eaoh) |
| 06/23/2009 | CA2252535C A pharmaceutical formulation containing growth hormone, an amino acid and a non-ionic detergent |
| 06/23/2009 | CA2251696C Genetic suppression and replacement |
| 06/23/2009 | CA2250078C Processes for the replication of influenza viruses in cell culture, and the influenza viruses obtainable by the process |
| 06/23/2009 | CA2173822C Cytoplasmic expression of antibodies, antibody fragments and antibody fragment fusion molecules in e. coli |
| 06/23/2009 | CA2139100C New sequences of hepatitis c virus genotypes and their use as therapeutic and diagnostic agents |
| 06/23/2009 | CA1341597C Mutant human tissue-type plasminogen activator with a modified carbohydrate structure at amino acid residue 117 |
| 06/19/2009 | CA2671983A1 Uses of cerberus, coco and derivatives thereof |
| 06/18/2009 | WO2009076672A1 Advantageous salts of mu-opiate receptor peptides |
| 06/18/2009 | WO2009076620A1 Nanoparticulate anidulafungin compositions and methods for making the same |
| 06/18/2009 | WO2009076587A1 Treatment of melanoma with alpha thymosin peptides in combination with a kinase inhibitor |
| 06/18/2009 | WO2009076580A2 Compositions and methods for the treatment and prevention of cardiovascular diseases |
| 06/18/2009 | WO2009076506A2 Gamma glutamylcysteine treatment or prevention of oxidative injury |
| 06/18/2009 | WO2009076475A1 Protein having pesticidal activity |
| 06/18/2009 | WO2009076428A1 Substituted 1,3-cyclopentadione multi-target protein kinase modulators of cancer, angiogenesis and the inflammatory pathways associated therewith |
| 06/18/2009 | WO2009076195A1 Treatment of drug-induced nausea with opioid antagonists |
| 06/18/2009 | WO2009076166A2 Oximyl hcv serine protease inhibitors |
| 06/18/2009 | WO2009076105A2 Co-administration of an agent linked to an internalization peptide with an anti-inflammatory |
| 06/18/2009 | WO2009075881A2 Impaired wound healing compositions and treatments |
| 06/18/2009 | WO2009075854A2 Effective quantitation of complex peptide mixtures in tissue samples and improved therapeutic methods |
| 06/18/2009 | WO2009075838A2 Treatment of menorrhagia with aromatase inhibitor |
| 06/18/2009 | WO2009075836A2 Rap variants for drug delivery |
| 06/18/2009 | WO2009075816A1 Combination enzyme therapy for gastric digestion of dietary gluten in celiac sprue patients |
| 06/18/2009 | WO2009075813A1 Treatment of melanoma with alpha thymosin peptides in combination with antibodies against cytotoxic t lymphocyte-associated antigen 4 (ctla4) |
| 06/18/2009 | WO2009074969A2 Spingosine-1-phosphate, analogues and antagonists for use as medicaments |
| 06/18/2009 | WO2009074809A1 Sigma ligands and ikk / nf - kb inhibitors for medical treatment |
| 06/18/2009 | WO2009074797A1 Methods for inhibiting scarring |
| 06/18/2009 | WO2009074271A1 Peptides modulators of tubulin polymerisation |
| 06/18/2009 | WO2009074133A2 C-terminal ifapsoriasin fragments as antimicrobial peptides, the production thereof and use thereof |
| 06/18/2009 | WO2009073916A1 Improved treatment and prophylaxis |
| 06/18/2009 | WO2009073911A1 Treatment and prophylaxis |
| 06/18/2009 | WO2009073909A1 Cyclic, cystein-free protein |
| 06/18/2009 | WO2009073908A1 Reverse protein |
| 06/18/2009 | WO2009059289A3 Netrin-1 compositions and methods of use thereof |
| 06/18/2009 | WO2009059082A3 Method, composition, and article of manufacture for providing alpha-1 antitrypsin |
| 06/18/2009 | WO2009053536A3 Splice variants of gdnf and uses thereof |
| 06/18/2009 | WO2009046864A3 Use of the human pancreatic polypeptide as a therapeutic agent |
| 06/18/2009 | WO2009046847A3 Use of peptide ll-37 as a therapeutic agent |
| 06/18/2009 | WO2009046846A3 Use of il-1 receptor peptide, alone or in combination with peptide ll-37, as a therapeutic agent |
| 06/18/2009 | WO2009043476A3 Neuromedin s as a therapeutic agent |
| 06/18/2009 | WO2009043448A3 Neuromedin u-25 and neuromedin s as therapeutic agents |
| 06/18/2009 | WO2009043440A3 Use of il-1 receptor peptide, alone or in combination with d-ala-gln-octadecyl ester, as a therapeutic agent |
| 06/18/2009 | WO2009031835A4 Cell permeable nm23 recombinant proteins, polynucleotides encoding the same, and anti-metastatic composition comprising the same |
| 06/18/2009 | WO2009025806A3 Use of vegfr-2 inhibitors for treating metastatic cancer |
| 06/18/2009 | WO2008154012A3 Treatments involving glutaredoxins and similar agents |
| 06/18/2009 | WO2008145849A3 Pharmaceutical and/or cosmetic composition containing aconitase-activating active ingredients |
| 06/18/2009 | WO2008145848A3 Pharmaceutical and/or cosmetic composition containing peptides |
| 06/18/2009 | WO2008129426A3 Medicaments and methods to treat autoimmune disease and cancer |
| 06/18/2009 | WO2008109167A3 Variant activin receptor polypeptides and uses thereof |
| 06/18/2009 | WO2008101672A3 Agent for use in the case of fructose intolerance |
| 06/18/2009 | WO2007046834A3 Glp-1 agonists, compositions, methods and uses |
| 06/18/2009 | WO2004070002A3 Cell lines and host nucleic acid sequences related to infectious disease |
| 06/18/2009 | WO2004055156A3 A vegf variant that lacks vegfr-1 binding activity and its use in promotion of re-endothelization and prevention of in-stent restenosis |
| 06/18/2009 | WO2004024077A3 Novel composition and methods for the treatment of psoriasis |
| 06/18/2009 | WO2003089458A3 Conjugates of membrane translocating agents and pharmaceutically active agents |
| 06/18/2009 | WO2003072756A3 Cloning and characterization of slc26a8 and slc26a11 anion exchangers |
| 06/18/2009 | WO2003064599A3 Cancer genes |
| 06/18/2009 | WO2003060153A3 Irak-m is a negative regulator of toll-like receptor signaling |
| 06/18/2009 | WO2001085908A3 Clasp-1 transmembrane protein |
| 06/18/2009 | US20090157017 Bioresorbable foaming tissue dressing |
| 06/18/2009 | US20090156795 Encoding gastrointestinal contractile protein for use in modulating nutrient uptake and growth hormone and digestive enzyme secretion |
| 06/18/2009 | US20090156689 Method of enhancing biological activity of plant extracts |
| 06/18/2009 | US20090156687 Fab I and inhibition of apicomplexan parasites |
| 06/18/2009 | US20090156624 Methionine aminopeptidase-2 inhibitors and methods of use thereof |
| 06/18/2009 | US20090156541 for interfering with the DNA repair of double strand breaks (DSB); novel double-stranded nucleic acid molecules that act as baits and hijack the holocomplex of enzymes responsible of DNA DSB sensing, signaling and/or repair pathways |
| 06/18/2009 | US20090156539 Antisense oligonucleotides (odn) against smad7 and uses thereof in medical field |
| 06/18/2009 | US20090156537 Compositions and methods for diagnosing and treating asthma or other allergic or inflammatory diseases |
| 06/18/2009 | US20090156528 RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS C VIRUS (HCV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| 06/18/2009 | US20090156527 Antiviral oligonucleotides targeting viral families |
| 06/18/2009 | US20090156510 Use of notch signaling regulators for modulating osteogenesis |
| 06/18/2009 | US20090156509 Tri-peptide Inhibitors of Serine Elastases |
| 06/18/2009 | US20090156508 Synthetic peptide amides and dimeric forms thereof |
| 06/18/2009 | US20090156507 Cell permeable conjugates of peptides for inhibition of protein kinases |
| 06/18/2009 | US20090156506 determining Vascular Endothelial Growth Factor D (VEGF-D) concentration in a sample from human that has tuberous sclerosis complex (TSC) or a cystic or chylous lung disorder such as lymphangiomatosis, Pulmonary Langerhan's cell histiocytosis (PLCH), emphysema, Sjogren's syndrome with cystic lung disease |
| 06/18/2009 | US20090156505 Self-assembly and mineralization of peptide-amphiphile nanofibers |
| 06/18/2009 | US20090156504 Methods of treating blood cell depletion |
| 06/18/2009 | US20090156503 Cell penetrating peptides for intracellular delivery of molecules |
| 06/18/2009 | US20090156502 Vascular Leak Syndrome; polypeptide toxophore from a DT; has cytotoxicity comparable to that of a DT molecule |
| 06/18/2009 | US20090156501 Identification of ligands by selective amplification of cells transfected with receptors |
| 06/18/2009 | US20090156500 Neuregulins for prevention and treatment of damage from acute assault on vascular and neuronal tissue and as regulators of neuronal stem cell migration |
| 06/18/2009 | US20090156499 Antimicrobial Peptides and Methods of Identifying the Same |
| 06/18/2009 | US20090156498 Fusion proteins for delivery of gdnf to the cns |
| 06/18/2009 | US20090156497 Non-cytotoxic PAP mutants |
| 06/18/2009 | US20090156496 Methods and compositions for treating and preventing peripheral nerve damage |
| 06/18/2009 | US20090156495 Compositions and methods for modulating immune responses |